TP53 p.R337H Germline Variant among Women at Risk of Hereditary Breast Cancer in a Public Health System of Midwest Brazil

Author:

Corrêa Tatiana Strava12,Asprino Paula Fontes2,de Oliveira Eduarda Sabá Cordeiro3,Leite Ana Carolina Rathsam124,Weis Luiza256ORCID,Achatz Maria Isabel2,de Oliveira Claudiner Pereira7,Sandoval Renata Lazari12,Barroso-Sousa Romualdo26

Affiliation:

1. Hospital Sírio-Libanês, Centro de Oncologia de Brasília, Brasília 71635-610, DF, Brazil

2. Instituto de Ensino e Pesquisa do Hospital Sírio Libanês, São Paulo 01308-060, SP, Brazil

3. Faculdade de Medicina, Universidade de Brasilia (UNB), Brasília 70910-900, DF, Brazil

4. Hospital Materno Infantil de Brasília (HMIB), Asa Sul 70203-900, DF, Brazil

5. Instituto Hospital de Base do Distrito Federal (IHB-DF), Brasília 70330-150, DF, Brazil

6. DASA Oncology, Hospital Brasília, Brasília 71681-603, DF, Brazil

7. Unidade de Genética do Hospital de Apoio de Brasília, Secretaria de Saúde, Brasília 70684-831, DF, Brazil

Abstract

Despite the high prevalence of TP53 pathogenic variants (PV) carriers in the South and Southeast regions of Brazil, germline genetic testing for hereditary breast cancer (HBC) is not available in the Brazilian public health system, and the prevalence of Li-Fraumeni syndrome (LFS) is not well established in other regions of Brazil. We assessed the occurrence of TP53 p.R337H carriers among women treated for breast cancer (BC) between January 2021 and January 2022 at public hospitals of Brasilia, DF, Brazil. A total of 180 patients who met at least one of the NCCN criteria for HBC underwent germline testing; 44.4% performed out-of-pocket germline multigene panel testing, and 55.6% were tested for the p.R337H variant by allelic discrimination PCR. The median age at BC diagnosis was 43.5 years, 93% had invasive ductal carcinoma, 50% had estrogen receptor-positive/HER2 negative tumors, and 41% and 11% were diagnosed respectively at stage III and IV. Two patients (1.11%) harbored the p.R337H variant, and cascade family testing identified 20 additional carriers. The TP53 p.R337H detection rate was lower than that reported in other studies from south/southeast Brazil. Nonetheless, identifying TP53 PV carriers through genetic testing in the Brazilian public health system could guide cancer treatment and prevention.

Funder

Stand Up to Cancer

The Instituto de Ensino e Pesquisa do Hospital Sirio-Libanes

Publisher

MDPI AG

Reference28 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3